nach oben

Erschienen in:

13.04.2021 | Case Report

The Outcome and Safety of Re-challenge Lutetium-177 PSMA (¹⁷⁷Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report

verfasst von: Masha Maharaj, Lucille Heslop, Trisha Govender, Nisaar Korowlay, Aviral Singh, Partha Choudhary, Mike Sathekge

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 (¹⁷⁷Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably safe with attractive clinical responses. Re-challenge ¹⁷⁷Lu-PSMA therapy in early responders has been shown to be safe and effective. We report the use of low-dose Taxol-based chemotherapy (modified dose 25 mg/m² weekly × 6 weeks) as a radiosensitizer with re-challenge ¹⁷⁷Lu-PSMA therapy (4 cycles). In a period of 3 years, the patient underwent a total of 8 cycles of ¹⁷⁷Lu-PSMA with a cumulative dose of 51.8 GBq. All therapies were uneventful and well tolerated. There was a good response to re-challenge ¹⁷⁷Lu-PSMA therapy and low-dose docetaxel (Taxol-¹⁷⁷Lu-PSMA) with no recorded tumour resistance.

Kulkarni H, Schuchardt C, Singh A, Langbein T, Baum R. Early initiation of ¹⁷⁷Lu-PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer [Abstract]. J Nucl Med. 2018;59:529.CrossRef

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA -RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.CrossRef

Ahmadzadehfar H, Rahbar K, Essler M, Biersack HJ. PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients. Semin Nucl Med. 2020;50:98–109.CrossRef

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge¹⁷⁷Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1073–80.CrossRef

Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, et al. Early experience of rechallenge 177177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer. J Nucl Med. 2019;60:644–8.CrossRef

Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2015. National Cancer Institute, Bethesda. https://seer.cancer.gov/csr/1975_2015/. Accessed Oct 2020.

Leslie SW, Soon-Sutton TL, Sajjad H, Siref LE. Prostate cancer. https://www.ncbi.nlm.nih.gov/books/NBK470550/; 2020.

Jadvar H. Prostate cancer. Methods Mol Biol. 2011;727:265–90. https://doi.org/10.1007/978-1-61779-062-1_15.CrossRef

Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–40.CrossRef

10.

Kumar P. A new paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Rev Urol. 2003;5:S71–7.PubMedPubMedCentral

11.

Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG. Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action. Oncol Res. 2004;14:447–54.CrossRef

12.

Miyanaga S, Ninomiya I, Tsukada T, Okamoto K, Harada S, Nakanuma S, et al. Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells. Int J Oncol. 2016;48:517–24.CrossRef

13.

Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, et al. Therapeutic efficacy of ¹⁷⁷Lu-CHX-A’’-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009;69:92–104.CrossRef

14.

Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38:848.e9-848.e16.CrossRef

15.

Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M. Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors. Clin Nucl Med. 2019;44:e329–35.CrossRef

16.

Thakral Parul, Sen Ishita, Pant Vineet, Gupta Santosh Kumar, Dureja Sugandha, Kumari Jyotsna, et al. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using ¹⁷⁷Lu-DOTATATE and capecitabine/temozolomide (CAP/TEM). Br J Radiol. 2018;91:20170172.CrossRef

17.

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.CrossRef

18.

Gafita A, Wang H, Tauber R, D’Alessandria C, Weber WA, Eiber M. Exceptional 4-year response to ¹⁷⁷Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:2212–3.CrossRef

Titel: The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
verfasst von: Masha Maharaj
Lucille Heslop
Trisha Govender
Nisaar Korowlay
Aviral Singh
Partha Choudhary
Mike Sathekge
Publikationsdatum: 13.04.2021
Verlag: Springer Singapore
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 3/2021
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-021-00696-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Outcome and Safety of Re-challenge Lutetium-177 PSMA (¹⁷⁷Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Rosai-Dorfman Disease: Importance of 18F FDG PET/CT to Determine Extension and Extranodal Involvement

Change of Therapeutic Response Classification According to Recombinant Human Thyrotropin-Stimulated Thyroglobulin Measured at Different Time Points in Papillary Thyroid Carcinoma

Angiogenesis-Targeted 68Ga-DOTA-RGD2 PET/CT Imaging: a Potential Theranostic Application in the Case of Chondrosarcoma

One Versus Up-to-5 Lesion Measurements for Response Assessment by PERCIST in Patients with Lung Cancer

Extended Whole-body Ga-68 DOTATATE PET-CT in evaluating Tumour-Induced Osteomalacia: Case report and review of literature

KSNM 60 years: International Collaboration with Asian Nuclear Medicine Community